Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Alnylam Pharmaceuticals, Inc. or Qiagen N.V. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Alnylam Pharmaceuticals, Inc. and Qiagen N.V. compare based on key financial metrics to determine which better meets your investment needs.

About Alnylam Pharmaceuticals, Inc. and Qiagen N.V.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Latest Biotechnology and Alnylam Pharmaceuticals, Inc., Qiagen N.V. Stock News

As of July 31, 2026, Alnylam Pharmaceuticals, Inc. had a $27.5 billion market capitalization, compared to the Biotechnology median of $252.6 million. Alnylam Pharmaceuticals, Inc.’s stock is down 48.3% in 2026, down 24.4% in the previous five trading days and down 39.52% in the past year.

Currently, Alnylam Pharmaceuticals, Inc.’s price-earnings ratio is 36.6. Alnylam Pharmaceuticals, Inc.’s trailing 12-month revenue is $4.8 billion with a 16.1% net profit margin. Year-over-year quarterly sales growth most recently was 66.8%. Analysts expect adjusted earnings to reach $9.041 per share for the current fiscal year. Alnylam Pharmaceuticals, Inc. does not currently pay a dividend.

As of July 31, 2026, Qiagen N.V. had a $8.6 billion market cap, putting it in the 75th percentile of all stocks. Qiagen N.V.’s stock is down 12.5% in 2026, up 0.1% in the previous five trading days and down 22.23% in the past year.

Currently, Qiagen N.V.’s price-earnings ratio is 21.3. Qiagen N.V.’s trailing 12-month revenue is $2.1 billion with a 19.2% net profit margin. Year-over-year quarterly sales growth most recently was 1.8%. Analysts expect adjusted earnings to reach $2.440 per share for the current fiscal year. Qiagen N.V. currently has a 5.8% dividend yield.

How We Compare Alnylam Pharmaceuticals, Inc. and Qiagen N.V. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Alnylam Pharmaceuticals, Inc. and Qiagen N.V.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Alnylam Pharmaceuticals, Inc. and Qiagen N.V. Stock Value Grades

Company	Ticker	Value
Alnylam Pharmaceuticals, Inc.	ALNY	F
Qiagen N.V.	QGEN	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Alnylam Pharmaceuticals, Inc. has a Value Score of 8, which is Ultra Expensive. Qiagen N.V. has a Value Score of 41, which is Average.

The Value Stock Winner: No Clear Winner

Neither Alnylam Pharmaceuticals, Inc. or Qiagen N.V. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Alnylam Pharmaceuticals, Inc. or Qiagen N.V. is the better investment when it comes to value.

Alnylam Pharmaceuticals, Inc. and Qiagen N.V. Growth Grades

Company	Ticker	Growth
Alnylam Pharmaceuticals, Inc.	ALNY	D
Qiagen N.V.	QGEN	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Alnylam Pharmaceuticals, Inc. has a Growth Score of 32, which is Weak. Qiagen N.V. has a Growth Score of 56, which is Average.

The Growth Stock Winner: No Clear Winner

Neither Alnylam Pharmaceuticals, Inc. or Qiagen N.V. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Alnylam Pharmaceuticals, Inc. or Qiagen N.V. is the better investment when it comes to sustainable growth.

Alnylam Pharmaceuticals, Inc. and Qiagen N.V.’s Momentum Grades

Company	Ticker	Momentum
Alnylam Pharmaceuticals, Inc.	ALNY	F
Qiagen N.V.	QGEN	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Alnylam Pharmaceuticals, Inc. has a Momentum Score of 12, which is Very Weak. Qiagen N.V. has a Momentum Score of 45, which is Average.

The Momentum Stock Winner: No Clear Winner

Neither Alnylam Pharmaceuticals, Inc. or Qiagen N.V. has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Alnylam Pharmaceuticals, Inc. or Qiagen N.V. is the better investment when it comes to momentum.

Other Alnylam Pharmaceuticals, Inc. and Qiagen N.V. Grades

In addition to Value, Growth and Momentum, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Alnylam Pharmaceuticals, Inc. and Qiagen N.V. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Alnylam Pharmaceuticals, Inc. or Qiagen N.V. Stock?

Overall, Alnylam Pharmaceuticals, Inc. stock has a Value Score of 8, Growth Score of 32 and Momentum Score of 12.

Qiagen N.V. stock has a Value Score of 41, Growth Score of 56 and Momentum Score of 45.

Comparing Alnylam Pharmaceuticals, Inc. and Qiagen N.V.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.